Compare RYTM & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | CENX |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aluminum |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.9B |
| IPO Year | 2017 | 2004 |
| Metric | RYTM | CENX |
|---|---|---|
| Price | $85.69 | $67.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $131.14 | $63.00 |
| AVG Volume (30 Days) | 960.8K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $1,893,200,000.00 |
| Revenue This Year | $54.90 | $18.24 |
| Revenue Next Year | $86.58 | $10.47 |
| P/E Ratio | ★ N/A | $159.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.31 | $14.77 |
| 52 Week High | $122.20 | $68.69 |
| Indicator | RYTM | CENX |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 70.57 |
| Support Level | $84.39 | $45.49 |
| Resistance Level | $93.51 | N/A |
| Average True Range (ATR) | 4.21 | 3.54 |
| MACD | 0.73 | 1.22 |
| Stochastic Oscillator | 68.33 | 93.11 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. The company also owns a carbon anode production facility in the Netherlands.